Actively Recruiting
Tissue-resident Immune Cell Subsets in aGVHD
Led by Nanfang Hospital, Southern Medical University · Updated on 2024-11-27
40
Participants Needed
1
Research Sites
28 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).
CONDITIONS
Official Title
Tissue-resident Immune Cell Subsets in aGVHD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign the informed consent form
- Age 16 to 65 years old
- Clinically diagnosed with graft-versus-host disease (GVHD) for the first time or currently receiving GVHD treatment
You will not qualify if you...
- History of other tumors
- Poor compliance or mental disorders
- Infection with HIV or hepatitis C virus (HCV)
- Uncontrolled hepatitis B virus (HBV) infection
- Presence of other autoimmune diseases
- Judged unsuitable to participate by the researcher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Nanfang Hospital, Southern Medical University
Guangzhou, Other (Non U.s.), China, 510000
Actively Recruiting
Research Team
Y
Yiming Sun
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here